| abstract |
1. N- (4- (7-azabicyclo [2.2.1] heptan-7-yl) -2- (trifluoromethyl) phenyl) -4-oxo-5- (trifluoromethyl) -1,4-dihydroquinoline-3-carboxamide characterized as Form A.2. Form A according to claim 1, where this Form A is characterized by one or more peaks in the x-ray powder, selected from approximately 7.9, approximately 9.3, approximately 11.9, approximately 14.4, approximately 15.1, approximately 15, 8, approximately 17.0, approximately 17.7, approximately 19.3, approximately 20.1, approximately 21.4, approximately 21.8, approximately 23.4, approximately 23.8, approximately 25.6, approximately 26, 8, approximately 29.4, approximately 29.7, approximately 30.1, or approximately 31.2 °. 3. Form A according to claim 1 or 2, wherein this Form A is characterized by a peak at approximately 7.9 °, a peak at approximately 11.9 °, a peak at approximately 14.4 °, and a peak at approximately 15.8 ° in the powder x-ray. . Form A according to claim 1, where this Form A is characterized by a diffraction pattern shown in Figure 1.5. A pharmaceutical composition comprising Form A according to any one of claims 1 to 4 and a pharmaceutically acceptable adjuvant or carrier. The pharmaceutical composition of claim 5, further comprising an additional agent selected from a mucolytic agent, a bronchodilator, an antibiotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator other than Form A, or an alimentary (nutritional) agent. The pharmaceutical composition of claim 6, wherein this additional agent is a CFTR modulator other than Form A.8. A method for treating or alleviating the severity of a patient’s disease, wherein said disease is selected from cystic fibrosis, asthma, smoke-induced COPD, chronic bronchitis, rhinosin |